KNSA vs NVST: Which Stock Is the Better Buy?
Kiniksa Pharmaceuticals International, plc and Envista Holdings Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — KNSA vs NVST, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Kiniksa Pharmaceuticals International, plc (KNSA) | Envista Holdings Corporation (NVST) | |
|---|---|---|
| Market cap | $3.9B | $3.9B |
| Revenue (latest FY) | $677.56M | $2.72B |
| Net income (latest FY) | $59.01M | $47.00M |
| Revenue growth (5y CAGR) | — | 7.1% |
| Net margin | 8.7% | 1.7% |
| Return on equity | 10.4% | 1.5% |
| P/E ratio | 55.5 | 58.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 7 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full KNSA vs NVST breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open KNSA's full financials → Open NVST's full financials →More comparisons
Frequently asked questions
Which is bigger, KNSA or NVST?
Envista Holdings Corporation is larger by market capitalization — $3.9B versus $3.9B.
Which grows faster, KNSA or NVST?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.